The role of obesity in renal damage in patients with chronic heart failure

THE AIM: to study the functional state ofthe kidneys in patientswith chronic heart failure (CHF)and obesity. PATIENTS AND METH­ODS. 116 patients with CHF l-lll functional class (FC) 45-65 years old are divided into three comparable groups depending on body mass index (BMI). A physical examination was performed, evaluated the renal function, the level of leptin and adiponectin, assessed the insulin resistance index, the combined risk of progression of chronic kidney disease (CKD), and the development of cardiovascular complications was analyzed. RESULTS. Among patients with CHF and obesity, a statistically significant decrease in glomerular filtration rate (GFR) was observed compared with patients of the 1st group (61.3 [46.2; 67.1] vs 73.2 [62.1; 86.3] ml/min / 1.73 m2), a clinically significant decrease in GFR <60 ml/min /1.73 m2 (CKD C3a-3b), high (A2) and very high (A3) albu­minuria (AU) compared in patientswith normal and overweight. The leptin concentration significantly increased from the 1st to the 3rd group, while the adiponectin concentration decreased from the 1st to the 3rd group. Statistically significant correlations were established between the concentration of leptin and GFR (r = -0.52), AC (r = 0.36), between the concentration of adiponectin and GFR (r = 0.38), AC (r = -0.32). Significant associations were found among patientswith overweight and obesity between the severity of AU, GFR, and HOMA-IR, metabolic index. CONCLUSION. A significant deterioration in the functional parameters ofthe kidneys in patientswith CHF with increasing body weight, as well as an increase in the combined risk of CKD progression and the development of cardiovascular complications with comparable FC, was established. The revealed reliable relationships reflect the significant pathogenetic contribution of the hormonal activity of visceral adipose tissue and insulin resistance to the development and progression of renal dysfunction in patients with heart failure and obesity.

1. Shlyakhto EV, Nedogoda SV, Konradi AO. National clinical recommendations «Diagnosis, treatment, prevention of obesity and associated diseases». St. Petersburg, 2017;1-164 (ln Russ.)

2. Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart 2017;103(23):1848-1853. doi: 10.1136/heartjnl-2016-310794

3. Nasibullina AA, Bulashova OV, Oslopov VN et al. The clinical characteristics of patients with heart failure in combination with chronic kidney diseas. The Bulletin of Contemporary Clinical Medi­cine 2015;8(Suppl. 1):85-89 (In Russ.)

4. Moiseev VS, Mukhin NA, Smirnov AVetal. Clinical guidelines. Cardiovascular risk and chronic kidney disease: cardionephropro- tection. Russian Journal of Cardiology 20t4\8( 112):7-37 (In Russ.), doi: 10.15829/1560-4071-2014-8-7-37

5. Garofalo C, Borrelli S, Minutolo R et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91(5): 1224-1235. doi: 10.1016/j.kint.2016.12.013

6. Russian Cardiology Society. National Society of Specialists in Myocardial Disease and Heart Failure. Society of Heart Failure Specialists. Clinical recommendations 2019 (In Russ.)

7. Smirnov AV, Shilov EM, Dobronravov VAet al. National guide­lines. Chronic kidney disease: basic principles of screening, diag­nosis, prevention and treatment approaches 2019 (In Russ.) http://nonr.ru/wp-content/uploads/2020/01/Clin_guidlines_CKD_24.11_final-3-3.pdf

8. Nedogoda SV, Barykina IN, Salasyuk AS. National clinical recommendations for obesity: concept and perspectives. Vestnik Voigogradskogo gosudarstvennogo meditsinskogo universiteta 2017;1(61):134-140 (ln Russ.)

9. Amato MC. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardio- metabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011;10(183):1-8

10. Roytberg GE, Dorosh JV, Sharkhun OO et al. New metabolic index use potentialities in evaluation of insulin resistance in clinical practice. Rational Pharmacotherapy in Cardiology 2014; 10(3) :264- 274 (In Russ.), doi: 10.20996/1819-6446-2014-10-3-264-274

11. Foster MC, Hwang SJ, Larson MG et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008;52(1):39-48. doi: 10.1053/j. ajkd.2008.03.003

12. Popova IR, Torchinskiy NV, DrapkinaO, Ivashkin VT Assess­ment of real function in patiens with overweight and obesity. The Clinician 2012;6(2):36-40 (In Russ.), doi: 10.17650/1818-8338­2012-6-2-36-40

13. Reznik EV, Nikitin IG. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiol­ogy. The Russian Archives of Internal Medicine 2019;9 (1):5-22 (In Russ.), doi: 10.20514/2226-6704-2019-9-1-5-22

14. Kobalava ZD, Villevalde SV, Bogmanova NK et al. The prevalence of chronic kidney disease markers in arterial hyper­tension patients and relation with diabetes: results of epidemio­logical study KHRONOGRAPH. Russian Journal of Cardiology 2018;2(154):91-101 (In Russ.), doi: 10.15829/1560-4071-2018­2-91-101

15. Kuol-C,Wu P-H, LinY-Hetal. The association of adiponec- tin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. 2019 Jul 19;14(7):e0220158. doi: 10.1371 /journal.pone.0220158

16. Sharma K. The link between obesity and albuminuria: adi- ponectin and podocyte dysfunction. Kidney Int 2009;76:145-148

17. Zhong Yu J, Kalantar-Zadeh K, Rhee CM. Adiponectin and Leptin in Kidney Disease Patients: Diagnosis and Treatment Endocrine Disorders in Kidney Disease, pp.277-290 January 2019:10.1007/978-3-319-97765-2_20

18. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151:175-183

19. Ellington AA, MalikAR, KleeGGetal. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007;50:708-714

20. Shishkova UN, Minyailova NN, RovdaYul, Karakova LM. Mechanisms of kidney damage in obesity and metabolic syndrome (literature review). Mother and child in Kuzbass 2018;2(73):9-15 (In Russ.)

21. Artunc F, Schleicher E, Weigert С et al. The impact of in­sulin resistance on the kidney and vasculature. Nat Rev Nephrol 2016;12(12):721-737. doi: 10.1038/nrneph.2016.145

22. Ruster C, Wolf G. The role of the renin-angiotensin-aldos- terone system in obesity-related renal diseases. Semin Nephrol 2013;33:44-53

23. Noor S, Alam F, Fatima SS et al. Role of Leptin and dyslipi- demia in chronic kidney disease. PakJPharm Sci 2018;31 (3):893- 897

24. Vyalkova AA, Lebedeva EN, Krasikov SI et al. Clinical and pa- phogenical aspects of kidney damage in obesity (review). Nephrol­ogy (Saint-Petersburg) 2014;18(3):24-33 (In Russ.)

25. Saraheimo M, ForsblomC, Thorn Letal. Serum adiponec­tin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008;31(6):1165-1169. doi: 10.2337/ dc07-2306

26. Fedorova EYu, Kutirina IM et al. Mechanisms of the kidney damage in case of obesity (review). Nephrology and dialysis 2006;(2):3-12(lnRuss.)

27. Ahima RS. Linking adiponectin to proteinuria. JCI 2008;118(2):1619-1622

28. RishengX Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2(3): 133-141

29. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. Journal of Renal Nutrition 2011;21(1):82-86

30. Jeon WS, Park JW, Lee N et al. Urinary adiponectin con­centration is positively associated with micro- and macrovascular complications. Cardiovasc Diabet 2013; 12:137

31. Babenko АХ Bayrasheva VK. Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy? Meditsinskiy sovet 2015;(7):32-43 (In Russ.), doi: 10.21518/2079-701X-2015-7-32-43

32. Vyalkova AA, Lebedeva EN, Afonina SN et al. Kidney dis­eases and obesity: molecular relationship and new approaches to diagnosis (literature review). Nephrology (Saint-Petersburg) 2017;21(3):25-38 (In Russ.), doi: 10.24884/1561-6274-2017-3­25-38